- About
- Home
- Introduction
- Statistics
- Programs
- Dignet
- Gene
- GenePair
- BioSummarAI
- Help & Docs
- Documents
- Help
- FAQs
- Links
- Acknowledge
- Disclaimer
- Contact Us
Gene Information
Gene symbol: SLC30A8
Gene name: solute carrier family 30 (zinc transporter), member 8
HGNC ID: 20303
Related Genes
Related Sentences
| # | PMID | Sentence |
| 1 | 15331542 | Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. |
| 2 | 15331542 | SLC30A8, a novel member of the zinc transporter (ZnT) family, was identified by searching the human genomic and expressed sequence tag (EST) databases with the amino acid sequence of all known human ZnT. |
| 3 | 15331542 | Confocal immunofluorescence analysis revealed that a ZnT-8-EGFP (enhanced green fluorescent protein) fusion product colocalized with insulin in the secretory pathway granules of the insulin-secreting INS-1 cells. |
| 4 | 15331542 | Because ZnT-8 facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles, ZnT-8 may be a major component for providing zinc to insulin maturation and/or storage processes in insulin-secreting pancreatic beta-cells. |
| 5 | 15331542 | Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. |
| 6 | 15331542 | SLC30A8, a novel member of the zinc transporter (ZnT) family, was identified by searching the human genomic and expressed sequence tag (EST) databases with the amino acid sequence of all known human ZnT. |
| 7 | 15331542 | Confocal immunofluorescence analysis revealed that a ZnT-8-EGFP (enhanced green fluorescent protein) fusion product colocalized with insulin in the secretory pathway granules of the insulin-secreting INS-1 cells. |
| 8 | 15331542 | Because ZnT-8 facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles, ZnT-8 may be a major component for providing zinc to insulin maturation and/or storage processes in insulin-secreting pancreatic beta-cells. |
| 9 | 15331542 | Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. |
| 10 | 15331542 | SLC30A8, a novel member of the zinc transporter (ZnT) family, was identified by searching the human genomic and expressed sequence tag (EST) databases with the amino acid sequence of all known human ZnT. |
| 11 | 15331542 | Confocal immunofluorescence analysis revealed that a ZnT-8-EGFP (enhanced green fluorescent protein) fusion product colocalized with insulin in the secretory pathway granules of the insulin-secreting INS-1 cells. |
| 12 | 15331542 | Because ZnT-8 facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles, ZnT-8 may be a major component for providing zinc to insulin maturation and/or storage processes in insulin-secreting pancreatic beta-cells. |
| 13 | 15331542 | Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. |
| 14 | 15331542 | SLC30A8, a novel member of the zinc transporter (ZnT) family, was identified by searching the human genomic and expressed sequence tag (EST) databases with the amino acid sequence of all known human ZnT. |
| 15 | 15331542 | Confocal immunofluorescence analysis revealed that a ZnT-8-EGFP (enhanced green fluorescent protein) fusion product colocalized with insulin in the secretory pathway granules of the insulin-secreting INS-1 cells. |
| 16 | 15331542 | Because ZnT-8 facilitates the accumulation of zinc from the cytoplasm into intracellular vesicles, ZnT-8 may be a major component for providing zinc to insulin maturation and/or storage processes in insulin-secreting pancreatic beta-cells. |
| 17 | 17293876 | These loci include a non-synonymous polymorphism in the zinc transporter SLC30A8, which is expressed exclusively in insulin-producing beta-cells, and two linkage disequilibrium blocks that contain genes potentially involved in beta-cell development or function (IDE-KIF11-HHEX and EXT2-ALX4). |
| 18 | 17463246 | With collaborators (FUSION and WTCCC/UKT2D), we identified and confirmed three loci associated with T2D-in a noncoding region near CDKN2A and CDKN2B, in an intron of IGF2BP2, and an intron of CDKAL1-and replicated associations near HHEX and in SLC30A8 found by a recent whole-genome association study. |
| 19 | 17463248 | We identify T2D-associated variants in an intergenic region of chromosome 11p12, contribute to the identification of T2D-associated variants near the genes IGF2BP2 and CDKAL1 and the region of CDKN2A and CDKN2B, and confirm that variants near TCF7L2, SLC30A8, HHEX, FTO, PPARG, and KCNJ11 are associated with T2D risk. |
| 20 | 17463249 | We detected diabetes susceptibility loci in and around the genes CDKAL1, CDKN2A/CDKN2B, and IGF2BP2 and confirmed the recently described associations at HHEX/IDE and SLC30A8. |
| 21 | 17942684 | A high-ranking candidate, the zinc transporter ZnT8 (Slc30A8), was targeted by autoantibodies in 60-80% of new-onset T1D compared with <2% of controls and <3% type 2 diabetic and in up to 30% of patients with other autoimmune disorders with a T1D association. |
| 22 | 17942684 | ZnT8 antibodies (ZnTA) were found in 26% of T1D subjects classified as autoantibody-negative on the basis of existing markers [glutamate decarboxylase (GADA), protein tyrosine phosphatase IA2 (IA2A), antibodies to insulin (IAA), and islet cytoplasmic autoantibodies (ICA)]. |
| 23 | 17942684 | A high-ranking candidate, the zinc transporter ZnT8 (Slc30A8), was targeted by autoantibodies in 60-80% of new-onset T1D compared with <2% of controls and <3% type 2 diabetic and in up to 30% of patients with other autoimmune disorders with a T1D association. |
| 24 | 17942684 | ZnT8 antibodies (ZnTA) were found in 26% of T1D subjects classified as autoantibody-negative on the basis of existing markers [glutamate decarboxylase (GADA), protein tyrosine phosphatase IA2 (IA2A), antibodies to insulin (IAA), and islet cytoplasmic autoantibodies (ICA)]. |
| 25 | 18162508 | Association of CDKAL1, IGF2BP2, CDKN2A/B, HHEX, SLC30A8, and KCNJ11 with susceptibility to type 2 diabetes in a Japanese population. |
| 26 | 18162509 | A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. |
| 27 | 18210030 | The French prospective D.E.S.I.R. study (N = 4,707) was genotyped for 22 polymorphisms within 14 loci showing nominal to strong association with T2D in recently published GWA analyses (CDKAL1, IGFBP2, CDKN2A/2B, EXT2, HHEX, LOC646279, SLC30A8, MMP26, KCTD12, LDLR, CAMTA1, LOC38776, NGN3 and CXCR4). |
| 28 | 18210030 | Individuals carrying T2D risk alleles of CDKAL1 or SLC30A8 had lower fasting plasma insulin level (rs7756992 P = 0.003) or lower basal insulin secretion (rs13266634 P = 0.0005), respectively, than non-carriers. |
| 29 | 18210030 | We confirmed deleterious effects of SLC30A8, CDKAL1, NGN3 and MMP26 risk alleles on glucose homeostasis in the D.E.S.I.R. prospective cohort. |
| 30 | 18210030 | The French prospective D.E.S.I.R. study (N = 4,707) was genotyped for 22 polymorphisms within 14 loci showing nominal to strong association with T2D in recently published GWA analyses (CDKAL1, IGFBP2, CDKN2A/2B, EXT2, HHEX, LOC646279, SLC30A8, MMP26, KCTD12, LDLR, CAMTA1, LOC38776, NGN3 and CXCR4). |
| 31 | 18210030 | Individuals carrying T2D risk alleles of CDKAL1 or SLC30A8 had lower fasting plasma insulin level (rs7756992 P = 0.003) or lower basal insulin secretion (rs13266634 P = 0.0005), respectively, than non-carriers. |
| 32 | 18210030 | We confirmed deleterious effects of SLC30A8, CDKAL1, NGN3 and MMP26 risk alleles on glucose homeostasis in the D.E.S.I.R. prospective cohort. |
| 33 | 18210030 | The French prospective D.E.S.I.R. study (N = 4,707) was genotyped for 22 polymorphisms within 14 loci showing nominal to strong association with T2D in recently published GWA analyses (CDKAL1, IGFBP2, CDKN2A/2B, EXT2, HHEX, LOC646279, SLC30A8, MMP26, KCTD12, LDLR, CAMTA1, LOC38776, NGN3 and CXCR4). |
| 34 | 18210030 | Individuals carrying T2D risk alleles of CDKAL1 or SLC30A8 had lower fasting plasma insulin level (rs7756992 P = 0.003) or lower basal insulin secretion (rs13266634 P = 0.0005), respectively, than non-carriers. |
| 35 | 18210030 | We confirmed deleterious effects of SLC30A8, CDKAL1, NGN3 and MMP26 risk alleles on glucose homeostasis in the D.E.S.I.R. prospective cohort. |
| 36 | 18264689 | Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. |
| 37 | 18321746 | One protein is the zinc transporter ZnT-8 that supplies pancreatic beta-cells with zinc. |
| 38 | 18324385 | The common SLC30A8 Arg325Trp variant is associated with reduced first-phase insulin release in 846 non-diabetic offspring of type 2 diabetes patients--the EUGENE2 study. |
| 39 | 18400535 | SLC30A8 encodes a beta-cell specific zinc-ion transporter and rs13266634 has been shown to affect insulin secretion. |
| 40 | 18469204 | Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 Asians. |
| 41 | 18548165 | Among them are the ligand to the vesicular monoamine transporter type 2 (VMAT-2), which is called dihydrotetrabenazine (DTBZ), antibodies to zinc transporter (ZnT-8) and the monoclonal antibody IC2. |
| 42 | 18548165 | While DTBZ and antibodies to ZnT-8 showed binding activities to more than beta-cells, the anti-IC2 monoclonal antibody showed binding properties exclusively to insulin-producing beta-cells. |
| 43 | 18548165 | Among them are the ligand to the vesicular monoamine transporter type 2 (VMAT-2), which is called dihydrotetrabenazine (DTBZ), antibodies to zinc transporter (ZnT-8) and the monoclonal antibody IC2. |
| 44 | 18548165 | While DTBZ and antibodies to ZnT-8 showed binding activities to more than beta-cells, the anti-IC2 monoclonal antibody showed binding properties exclusively to insulin-producing beta-cells. |
| 45 | 18548167 | SLC30A8 (ZnT8) Polymorphism is Associated with Young Age at Type 1 Diabetes Onset. |
| 46 | 18548167 | It was recently shown that the major allele of the SLC30A8 (zinc transporter 8, ZnT8) single nucleotide polymorphism (SNP) rs13266634 was associated with type 2 diabetes and with reduced insulin secretion in non-diabetic relatives. |
| 47 | 18548167 | SLC30A8 (ZnT8) Polymorphism is Associated with Young Age at Type 1 Diabetes Onset. |
| 48 | 18548167 | It was recently shown that the major allele of the SLC30A8 (zinc transporter 8, ZnT8) single nucleotide polymorphism (SNP) rs13266634 was associated with type 2 diabetes and with reduced insulin secretion in non-diabetic relatives. |
| 49 | 18628523 | Zinc transporter-8 gene (SLC30A8) is associated with type 2 diabetes in Chinese. |
| 50 | 18633108 | Common variants in CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, and HHEX/IDE genes are associated with type 2 diabetes and impaired fasting glucose in a Chinese Han population. |
| 51 | 18991055 | Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population. |
| 52 | 18991055 | The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population. |
| 53 | 18991055 | Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated. |
| 54 | 18991055 | In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population. |
| 55 | 18991055 | Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population. |
| 56 | 18991055 | The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population. |
| 57 | 18991055 | Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated. |
| 58 | 18991055 | In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population. |
| 59 | 18991055 | Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population. |
| 60 | 18991055 | The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population. |
| 61 | 18991055 | Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated. |
| 62 | 18991055 | In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population. |
| 63 | 18991055 | Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population. |
| 64 | 18991055 | The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population. |
| 65 | 18991055 | Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated. |
| 66 | 18991055 | In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population. |
| 67 | 19008344 | Association analysis of variation in/near FTO, CDKAL1, SLC30A8, HHEX, EXT2, IGF2BP2, LOC387761, and CDKN2B with type 2 diabetes and related quantitative traits in Pima Indians. |
| 68 | 19057525 | Genes implied in human T2D development, TCF7L2, WFS1, FTO, SLC30A8, and GCKR, were mapped on Sus scrofa chromosomes 14, 8, 6, 4, and 3, respectively. |
| 69 | 19082521 | We analysed 23 SNPs in 9 T2DM genes (CDKAL1, CDKN2B, HHEX/IDE, IGF2BP2, KCNJ11, SLC30A8, TCF2, TCF7L2 and WFS1) in a maximum of 712 men and women from the Quebec Family Study. |
| 70 | 19082521 | We confirmed the significant associations of variants in CDKAL1, CDKN2B, HHEX/IDE, KCNJ11 and TCF7L2 with insulin secretion and also found associations of some of these variants with insulin sensitivity and glucose tolerance. |
| 71 | 19082521 | IGF2BP2 and SLC30A8 SNPs were not associated with insulin secretion but were with insulin sensitivity and glucose tolerance (0.002 <or= P <or= 0.02). |
| 72 | 19082521 | Diabetes-associated variants in CDKAL1, CDKN2B, HHEX/IDE, IGF2BP2, KCNJ11, SLC30A8 and TCF7L2 are associated with physiological alterations leading to T2DM, such as glucose intolerance, impaired insulin secretion or insulin resistance, supporting their role in the disease aetiology. |
| 73 | 19082521 | We analysed 23 SNPs in 9 T2DM genes (CDKAL1, CDKN2B, HHEX/IDE, IGF2BP2, KCNJ11, SLC30A8, TCF2, TCF7L2 and WFS1) in a maximum of 712 men and women from the Quebec Family Study. |
| 74 | 19082521 | We confirmed the significant associations of variants in CDKAL1, CDKN2B, HHEX/IDE, KCNJ11 and TCF7L2 with insulin secretion and also found associations of some of these variants with insulin sensitivity and glucose tolerance. |
| 75 | 19082521 | IGF2BP2 and SLC30A8 SNPs were not associated with insulin secretion but were with insulin sensitivity and glucose tolerance (0.002 <or= P <or= 0.02). |
| 76 | 19082521 | Diabetes-associated variants in CDKAL1, CDKN2B, HHEX/IDE, IGF2BP2, KCNJ11, SLC30A8 and TCF7L2 are associated with physiological alterations leading to T2DM, such as glucose intolerance, impaired insulin secretion or insulin resistance, supporting their role in the disease aetiology. |
| 77 | 19082521 | We analysed 23 SNPs in 9 T2DM genes (CDKAL1, CDKN2B, HHEX/IDE, IGF2BP2, KCNJ11, SLC30A8, TCF2, TCF7L2 and WFS1) in a maximum of 712 men and women from the Quebec Family Study. |
| 78 | 19082521 | We confirmed the significant associations of variants in CDKAL1, CDKN2B, HHEX/IDE, KCNJ11 and TCF7L2 with insulin secretion and also found associations of some of these variants with insulin sensitivity and glucose tolerance. |
| 79 | 19082521 | IGF2BP2 and SLC30A8 SNPs were not associated with insulin secretion but were with insulin sensitivity and glucose tolerance (0.002 <or= P <or= 0.02). |
| 80 | 19082521 | Diabetes-associated variants in CDKAL1, CDKN2B, HHEX/IDE, IGF2BP2, KCNJ11, SLC30A8 and TCF7L2 are associated with physiological alterations leading to T2DM, such as glucose intolerance, impaired insulin secretion or insulin resistance, supporting their role in the disease aetiology. |
| 81 | 19095428 | Diabetes-linked zinc transporter ZnT8 is a homodimeric protein expressed by distinct rodent endocrine cell types in the pancreas and other glands. |
| 82 | 19096518 | Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. |
| 83 | 19096518 | The results show that glycated hemoglobin levels are associated with genetic variation at the GCK (rs730497; P = 2.8 x 10(-12)), SLC30A8 (rs13266634; P = 9.8 x 10(-8)), G6PC2 (rs1402837; P = 6.8 x 10(-10)), and HK1 (rs7072268; P = 6.4 x 10(-9)) loci. |
| 84 | 19096518 | While associations at the GCK, SLC30A8, and G6PC2 loci are confirmatory, the findings at HK1 are novel. |
| 85 | 19096518 | This observed genetic association between glycated hemoglobin levels and HK1 polymorphisms paves the way for further studies of the role of HK1 in hemoglobin glycation, glucose metabolism, and diabetes. |
| 86 | 19096518 | Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. |
| 87 | 19096518 | The results show that glycated hemoglobin levels are associated with genetic variation at the GCK (rs730497; P = 2.8 x 10(-12)), SLC30A8 (rs13266634; P = 9.8 x 10(-8)), G6PC2 (rs1402837; P = 6.8 x 10(-10)), and HK1 (rs7072268; P = 6.4 x 10(-9)) loci. |
| 88 | 19096518 | While associations at the GCK, SLC30A8, and G6PC2 loci are confirmatory, the findings at HK1 are novel. |
| 89 | 19096518 | This observed genetic association between glycated hemoglobin levels and HK1 polymorphisms paves the way for further studies of the role of HK1 in hemoglobin glycation, glucose metabolism, and diabetes. |
| 90 | 19120306 | The human zinc transporter Slc30A8 (ZnT8) is a major target of humoral autoimmunity in human type 1A diabetes. |
| 91 | 19120307 | The highest ranking candidate was Slc30A8 (zinc transporter 8; ZnT8), which was screened by radioimmunoprecipitation assays against new-onset T1D and prediabetic sera. |
| 92 | 19120307 | ZnT8 autoantibodies were found, however, in 26% of T1D subjects previously classified as autoantibody-negative on the basis of existing markers (GADA, IA2 A, IAA, and ICA). |
| 93 | 19120307 | The highest ranking candidate was Slc30A8 (zinc transporter 8; ZnT8), which was screened by radioimmunoprecipitation assays against new-onset T1D and prediabetic sera. |
| 94 | 19120307 | ZnT8 autoantibodies were found, however, in 26% of T1D subjects previously classified as autoantibody-negative on the basis of existing markers (GADA, IA2 A, IAA, and ICA). |
| 95 | 19247372 | We then selected 11 genes, KCNQ1, TCF7L2, CDKAL1, CDKN2A/B, IGF2BP2, SLC30A8, HHEX, GCKR, HNF1B, KCNJ11 and PPARG, whose associations with diabetes have already been reported and replicated either in the literature or in this study in the Japanese population. |
| 96 | 19479076 | Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion. |
| 97 | 19479076 | The SLC30A8 gene codes for a pancreatic beta-cell-expressed zinc transporter, ZnT8. |
| 98 | 19479076 | ZnT8-downregulated cells showed reduced insulin content and decreased insulin secretion (expressed as percent of total insulin content) in response to hyperglycemic stimulus, as determined by insulin immunoassay. |
| 99 | 19479076 | These data indicate that reduced ZnT8 expression in cultured pancreatic beta cells gives rise to a reduced insulin response to hyperglycemia. |
| 100 | 19479076 | In addition, although we provide no direct evidence, these data suggest that an SLC30A8 expression-level polymorphism could affect insulin secretion and the glycemic response in vivo. |
| 101 | 19479076 | Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion. |
| 102 | 19479076 | The SLC30A8 gene codes for a pancreatic beta-cell-expressed zinc transporter, ZnT8. |
| 103 | 19479076 | ZnT8-downregulated cells showed reduced insulin content and decreased insulin secretion (expressed as percent of total insulin content) in response to hyperglycemic stimulus, as determined by insulin immunoassay. |
| 104 | 19479076 | These data indicate that reduced ZnT8 expression in cultured pancreatic beta cells gives rise to a reduced insulin response to hyperglycemia. |
| 105 | 19479076 | In addition, although we provide no direct evidence, these data suggest that an SLC30A8 expression-level polymorphism could affect insulin secretion and the glycemic response in vivo. |
| 106 | 19479076 | Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion. |
| 107 | 19479076 | The SLC30A8 gene codes for a pancreatic beta-cell-expressed zinc transporter, ZnT8. |
| 108 | 19479076 | ZnT8-downregulated cells showed reduced insulin content and decreased insulin secretion (expressed as percent of total insulin content) in response to hyperglycemic stimulus, as determined by insulin immunoassay. |
| 109 | 19479076 | These data indicate that reduced ZnT8 expression in cultured pancreatic beta cells gives rise to a reduced insulin response to hyperglycemia. |
| 110 | 19479076 | In addition, although we provide no direct evidence, these data suggest that an SLC30A8 expression-level polymorphism could affect insulin secretion and the glycemic response in vivo. |
| 111 | 19479076 | Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion. |
| 112 | 19479076 | The SLC30A8 gene codes for a pancreatic beta-cell-expressed zinc transporter, ZnT8. |
| 113 | 19479076 | ZnT8-downregulated cells showed reduced insulin content and decreased insulin secretion (expressed as percent of total insulin content) in response to hyperglycemic stimulus, as determined by insulin immunoassay. |
| 114 | 19479076 | These data indicate that reduced ZnT8 expression in cultured pancreatic beta cells gives rise to a reduced insulin response to hyperglycemia. |
| 115 | 19479076 | In addition, although we provide no direct evidence, these data suggest that an SLC30A8 expression-level polymorphism could affect insulin secretion and the glycemic response in vivo. |
| 116 | 19479076 | Down-regulation of ZnT8 expression in INS-1 rat pancreatic beta cells reduces insulin content and glucose-inducible insulin secretion. |
| 117 | 19479076 | The SLC30A8 gene codes for a pancreatic beta-cell-expressed zinc transporter, ZnT8. |
| 118 | 19479076 | ZnT8-downregulated cells showed reduced insulin content and decreased insulin secretion (expressed as percent of total insulin content) in response to hyperglycemic stimulus, as determined by insulin immunoassay. |
| 119 | 19479076 | These data indicate that reduced ZnT8 expression in cultured pancreatic beta cells gives rise to a reduced insulin response to hyperglycemia. |
| 120 | 19479076 | In addition, although we provide no direct evidence, these data suggest that an SLC30A8 expression-level polymorphism could affect insulin secretion and the glycemic response in vivo. |
| 121 | 19542200 | Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes-associated variants. |
| 122 | 19590848 | Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. |
| 123 | 19655390 | In pancreatic islets, insulin production is linked with zinc transport mediated by zinc transporter ZnT-8, a product of the SLC30A8 gene. |
| 124 | 19655390 | Therefore, altered activity of ZnT-8 is expected to be associated with impaired glucose-induced insulin response and promote progression from glucose intolerance to diabetes. |
| 125 | 19655390 | In pancreatic islets, insulin production is linked with zinc transport mediated by zinc transporter ZnT-8, a product of the SLC30A8 gene. |
| 126 | 19655390 | Therefore, altered activity of ZnT-8 is expected to be associated with impaired glucose-induced insulin response and promote progression from glucose intolerance to diabetes. |
| 127 | 19706465 | Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. |
| 128 | 19706465 | In this study we assessed the role of the zinc transporter ZnT8 using ZnT8-knockout (ZnT8(-/-)) mice. |
| 129 | 19706465 | Absence of ZnT8 expression caused loss of zinc release upon stimulation of exocytosis, but normal rates of insulin biosynthesis, normal insulin content and preserved glucose-induced insulin release. |
| 130 | 19706465 | Ultrastructurally, mature dense core insulin granules were rare in ZnT8(-/-) beta cells and were replaced by immature, pale insulin "progranules," which were larger than in ZnT8(+/+) islets. |
| 131 | 19706465 | Our data show that the ZnT8 transporter is essential for the formation of insulin crystals in beta cells, contributing to the packaging efficiency of stored insulin. |
| 132 | 19706465 | Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. |
| 133 | 19706465 | In this study we assessed the role of the zinc transporter ZnT8 using ZnT8-knockout (ZnT8(-/-)) mice. |
| 134 | 19706465 | Absence of ZnT8 expression caused loss of zinc release upon stimulation of exocytosis, but normal rates of insulin biosynthesis, normal insulin content and preserved glucose-induced insulin release. |
| 135 | 19706465 | Ultrastructurally, mature dense core insulin granules were rare in ZnT8(-/-) beta cells and were replaced by immature, pale insulin "progranules," which were larger than in ZnT8(+/+) islets. |
| 136 | 19706465 | Our data show that the ZnT8 transporter is essential for the formation of insulin crystals in beta cells, contributing to the packaging efficiency of stored insulin. |
| 137 | 19706465 | Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. |
| 138 | 19706465 | In this study we assessed the role of the zinc transporter ZnT8 using ZnT8-knockout (ZnT8(-/-)) mice. |
| 139 | 19706465 | Absence of ZnT8 expression caused loss of zinc release upon stimulation of exocytosis, but normal rates of insulin biosynthesis, normal insulin content and preserved glucose-induced insulin release. |
| 140 | 19706465 | Ultrastructurally, mature dense core insulin granules were rare in ZnT8(-/-) beta cells and were replaced by immature, pale insulin "progranules," which were larger than in ZnT8(+/+) islets. |
| 141 | 19706465 | Our data show that the ZnT8 transporter is essential for the formation of insulin crystals in beta cells, contributing to the packaging efficiency of stored insulin. |
| 142 | 19706465 | Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. |
| 143 | 19706465 | In this study we assessed the role of the zinc transporter ZnT8 using ZnT8-knockout (ZnT8(-/-)) mice. |
| 144 | 19706465 | Absence of ZnT8 expression caused loss of zinc release upon stimulation of exocytosis, but normal rates of insulin biosynthesis, normal insulin content and preserved glucose-induced insulin release. |
| 145 | 19706465 | Ultrastructurally, mature dense core insulin granules were rare in ZnT8(-/-) beta cells and were replaced by immature, pale insulin "progranules," which were larger than in ZnT8(+/+) islets. |
| 146 | 19706465 | Our data show that the ZnT8 transporter is essential for the formation of insulin crystals in beta cells, contributing to the packaging efficiency of stored insulin. |
| 147 | 19706465 | Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice. |
| 148 | 19706465 | In this study we assessed the role of the zinc transporter ZnT8 using ZnT8-knockout (ZnT8(-/-)) mice. |
| 149 | 19706465 | Absence of ZnT8 expression caused loss of zinc release upon stimulation of exocytosis, but normal rates of insulin biosynthesis, normal insulin content and preserved glucose-induced insulin release. |
| 150 | 19706465 | Ultrastructurally, mature dense core insulin granules were rare in ZnT8(-/-) beta cells and were replaced by immature, pale insulin "progranules," which were larger than in ZnT8(+/+) islets. |
| 151 | 19706465 | Our data show that the ZnT8 transporter is essential for the formation of insulin crystals in beta cells, contributing to the packaging efficiency of stored insulin. |
| 152 | 19817803 | The link between zinc, diabetes and islet dysfunction has recently been reiterated by genomewide association studies that identified an islet cell membrane zinc transporter, SLC30A8 (ZnT8), as one of the risk loci for type 2 diabetes. |
| 153 | 19862325 | PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 and SLC30A8 are associated with type 2 diabetes in a Chinese population. |
| 154 | 20007922 | For instance, no conclusive support for a role of the T1D-associated INS gene has been reported in T2D; conversely, but similarly, no evidence has been found for the role of the T2D-associated genes IDE/HHEX, SLC30A8, CDKAL1, CDKN2A/B, IGF2BP2, FTO, and TCF7L2 in T1D. |
| 155 | 20034370 | These include zinc importers, ZIP1, ZIP10, and ZIP14 of the SLC39A family and zinc exporters, ZnT1, and ZnT4-8 of the SLC30A family. |
| 156 | 20034370 | The ZnT8 protein has emerged as particularly interesting since this zinc transporter has been identified as a genetic risk factor for the development of both type 1 and type 2 diabetes in which both alpha- and beta-cell functions are affected. |
| 157 | 20035758 | In the present study, we created a chimeric protein, IA2-ZnT8WR, with two major islet autoantigens, IA-2 and the recent Zinc transporter 8 (ZnT8). |
| 158 | 20035758 | The chimeric molecule included both common polymorphisms of the ZnT8 molecule, arginine or tryptophan at position 325. |
| 159 | 20035758 | Autoantibodies to the chimeric molecule were compared to reactivity with individual assays detecting autoantibodies reacting with the separate molecules (IA-2, ZnT8-R and ZnT8-W). |
| 160 | 20035758 | With this chimeric protein antigen, IA2-ZnT8WR, one radioassay is able to detect autoantibodies to IA-2 and to both major forms of ZnT8 (100% sensitivity, 100% unchanged specificity, relative to individual molecules). |
| 161 | 20035758 | The chimeric assay provides an efficient and economical technique to screen for islet autoantibodies reacting with IA-2 and ZnT8. |
| 162 | 20035758 | In the present study, we created a chimeric protein, IA2-ZnT8WR, with two major islet autoantigens, IA-2 and the recent Zinc transporter 8 (ZnT8). |
| 163 | 20035758 | The chimeric molecule included both common polymorphisms of the ZnT8 molecule, arginine or tryptophan at position 325. |
| 164 | 20035758 | Autoantibodies to the chimeric molecule were compared to reactivity with individual assays detecting autoantibodies reacting with the separate molecules (IA-2, ZnT8-R and ZnT8-W). |
| 165 | 20035758 | With this chimeric protein antigen, IA2-ZnT8WR, one radioassay is able to detect autoantibodies to IA-2 and to both major forms of ZnT8 (100% sensitivity, 100% unchanged specificity, relative to individual molecules). |
| 166 | 20035758 | The chimeric assay provides an efficient and economical technique to screen for islet autoantibodies reacting with IA-2 and ZnT8. |
| 167 | 20035758 | In the present study, we created a chimeric protein, IA2-ZnT8WR, with two major islet autoantigens, IA-2 and the recent Zinc transporter 8 (ZnT8). |
| 168 | 20035758 | The chimeric molecule included both common polymorphisms of the ZnT8 molecule, arginine or tryptophan at position 325. |
| 169 | 20035758 | Autoantibodies to the chimeric molecule were compared to reactivity with individual assays detecting autoantibodies reacting with the separate molecules (IA-2, ZnT8-R and ZnT8-W). |
| 170 | 20035758 | With this chimeric protein antigen, IA2-ZnT8WR, one radioassay is able to detect autoantibodies to IA-2 and to both major forms of ZnT8 (100% sensitivity, 100% unchanged specificity, relative to individual molecules). |
| 171 | 20035758 | The chimeric assay provides an efficient and economical technique to screen for islet autoantibodies reacting with IA-2 and ZnT8. |
| 172 | 20035758 | In the present study, we created a chimeric protein, IA2-ZnT8WR, with two major islet autoantigens, IA-2 and the recent Zinc transporter 8 (ZnT8). |
| 173 | 20035758 | The chimeric molecule included both common polymorphisms of the ZnT8 molecule, arginine or tryptophan at position 325. |
| 174 | 20035758 | Autoantibodies to the chimeric molecule were compared to reactivity with individual assays detecting autoantibodies reacting with the separate molecules (IA-2, ZnT8-R and ZnT8-W). |
| 175 | 20035758 | With this chimeric protein antigen, IA2-ZnT8WR, one radioassay is able to detect autoantibodies to IA-2 and to both major forms of ZnT8 (100% sensitivity, 100% unchanged specificity, relative to individual molecules). |
| 176 | 20035758 | The chimeric assay provides an efficient and economical technique to screen for islet autoantibodies reacting with IA-2 and ZnT8. |
| 177 | 20142250 | We evaluated associations in the Atherosclerosis Risk in Communities study between PrCa and nine T2D single nucleotide polymorphisms from genome-wide association studies of T2D (in CDKAL1, CDKN2A/B, FTO, HHEX, IGF2BP2, KCNJ11, PPARG, SLC30A8, and TCF7L2) and four T2D single nucleotide polymorphisms from pre-genome-wide association studies (in ADRB2, CAPN10, SLC2A2, and UCP2). |
| 178 | 20142250 | PrCa was positively associated with the CAPN10 rs3792267 G allele [hazard ratio (HR) 1.20; 95% confidence interval (CI), 1.00-1.44] and inversely associated with the SLC2A2 rs5400 Thr110 allele (HR, 0.85; 95% CI, 0.72, 1.00), the UCP2 rs660339 Val55 allele (HR, 0.84; 95% CI, 0.73, 0.97) and the IGF2BP2 rs4402960 T allele (HR, 0.79; 95% CI, 0.61-1.02; blacks only). |
| 179 | 20351753 | A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion. |
| 180 | 20351753 | SLC30A8 encodes the β-cell-specific zinc transporter-8 (ZnT-8) expressed in insulin secretory granules. |
| 181 | 20351753 | We tested the hypothesis that the polymorphic residue at position 325 of ZnT-8 determines the susceptibility to cyclosporin A (CsA) suppression of insulin secretion. |
| 182 | 20351753 | A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently. |
| 183 | 20351753 | These data suggest that the ZnT-8 W325 variant is protective against CsA-induced suppression of insulin secretion. |
| 184 | 20351753 | A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion. |
| 185 | 20351753 | SLC30A8 encodes the β-cell-specific zinc transporter-8 (ZnT-8) expressed in insulin secretory granules. |
| 186 | 20351753 | We tested the hypothesis that the polymorphic residue at position 325 of ZnT-8 determines the susceptibility to cyclosporin A (CsA) suppression of insulin secretion. |
| 187 | 20351753 | A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently. |
| 188 | 20351753 | These data suggest that the ZnT-8 W325 variant is protective against CsA-induced suppression of insulin secretion. |
| 189 | 20351753 | A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion. |
| 190 | 20351753 | SLC30A8 encodes the β-cell-specific zinc transporter-8 (ZnT-8) expressed in insulin secretory granules. |
| 191 | 20351753 | We tested the hypothesis that the polymorphic residue at position 325 of ZnT-8 determines the susceptibility to cyclosporin A (CsA) suppression of insulin secretion. |
| 192 | 20351753 | A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently. |
| 193 | 20351753 | These data suggest that the ZnT-8 W325 variant is protective against CsA-induced suppression of insulin secretion. |
| 194 | 20351753 | A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion. |
| 195 | 20351753 | SLC30A8 encodes the β-cell-specific zinc transporter-8 (ZnT-8) expressed in insulin secretory granules. |
| 196 | 20351753 | We tested the hypothesis that the polymorphic residue at position 325 of ZnT-8 determines the susceptibility to cyclosporin A (CsA) suppression of insulin secretion. |
| 197 | 20351753 | A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently. |
| 198 | 20351753 | These data suggest that the ZnT-8 W325 variant is protective against CsA-induced suppression of insulin secretion. |
| 199 | 20351753 | A low-risk ZnT-8 allele (W325) for post-transplantation diabetes mellitus is protective against cyclosporin A-induced impairment of insulin secretion. |
| 200 | 20351753 | SLC30A8 encodes the β-cell-specific zinc transporter-8 (ZnT-8) expressed in insulin secretory granules. |
| 201 | 20351753 | We tested the hypothesis that the polymorphic residue at position 325 of ZnT-8 determines the susceptibility to cyclosporin A (CsA) suppression of insulin secretion. |
| 202 | 20351753 | A reduced number of insulin granule fusion events accompanied the decrease in insulin secretion in CsA-treated cells expressing ZnT-8 R325; however, ZnT-8 W325-expressing cells exhibited resistance to the dampening of insulin granule fusion by CsA, and transported zinc ions into secretory vesicles more efficiently. |
| 203 | 20351753 | These data suggest that the ZnT-8 W325 variant is protective against CsA-induced suppression of insulin secretion. |
| 204 | 20424228 | Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. |
| 205 | 20424817 | Beta cell-specific Znt8 deletion in mice causes marked defects in insulin processing, crystallisation and secretion. |
| 206 | 20490449 | The role of zinc in islet function has recently achieved new attention as a consequence of the identification of zinc transporter 8 (ZNT8) in islets, and the association of mutations in the gene for this zinc transporter with glucose intolerance and type 2 diabetes. |
| 207 | 20490449 | ZNT8 is also an autoantigen associated with the appearance of type 1 diabetes. |
| 208 | 20490449 | A number of experimental models have been employed to suggest how ZNT8 and other zinc transporters regulate beta cell insulin processing and possibly secretion. |
| 209 | 20490449 | In this issue of Diabetologia, Wijesekara and colleagues, using a cell-specific Znt8 (also known as Slc30a8) knockout model, demonstrate that beta cell insulin processing and glucose tolerance is negatively affected after beta cell knock out of Znt8, whereas Znt8 knockout in alpha cells seems to have little effect on glucagon secretion or glucose tolerance. |
| 210 | 20490449 | The role of zinc in islet function has recently achieved new attention as a consequence of the identification of zinc transporter 8 (ZNT8) in islets, and the association of mutations in the gene for this zinc transporter with glucose intolerance and type 2 diabetes. |
| 211 | 20490449 | ZNT8 is also an autoantigen associated with the appearance of type 1 diabetes. |
| 212 | 20490449 | A number of experimental models have been employed to suggest how ZNT8 and other zinc transporters regulate beta cell insulin processing and possibly secretion. |
| 213 | 20490449 | In this issue of Diabetologia, Wijesekara and colleagues, using a cell-specific Znt8 (also known as Slc30a8) knockout model, demonstrate that beta cell insulin processing and glucose tolerance is negatively affected after beta cell knock out of Znt8, whereas Znt8 knockout in alpha cells seems to have little effect on glucagon secretion or glucose tolerance. |
| 214 | 20490449 | The role of zinc in islet function has recently achieved new attention as a consequence of the identification of zinc transporter 8 (ZNT8) in islets, and the association of mutations in the gene for this zinc transporter with glucose intolerance and type 2 diabetes. |
| 215 | 20490449 | ZNT8 is also an autoantigen associated with the appearance of type 1 diabetes. |
| 216 | 20490449 | A number of experimental models have been employed to suggest how ZNT8 and other zinc transporters regulate beta cell insulin processing and possibly secretion. |
| 217 | 20490449 | In this issue of Diabetologia, Wijesekara and colleagues, using a cell-specific Znt8 (also known as Slc30a8) knockout model, demonstrate that beta cell insulin processing and glucose tolerance is negatively affected after beta cell knock out of Znt8, whereas Znt8 knockout in alpha cells seems to have little effect on glucagon secretion or glucose tolerance. |
| 218 | 20490449 | The role of zinc in islet function has recently achieved new attention as a consequence of the identification of zinc transporter 8 (ZNT8) in islets, and the association of mutations in the gene for this zinc transporter with glucose intolerance and type 2 diabetes. |
| 219 | 20490449 | ZNT8 is also an autoantigen associated with the appearance of type 1 diabetes. |
| 220 | 20490449 | A number of experimental models have been employed to suggest how ZNT8 and other zinc transporters regulate beta cell insulin processing and possibly secretion. |
| 221 | 20490449 | In this issue of Diabetologia, Wijesekara and colleagues, using a cell-specific Znt8 (also known as Slc30a8) knockout model, demonstrate that beta cell insulin processing and glucose tolerance is negatively affected after beta cell knock out of Znt8, whereas Znt8 knockout in alpha cells seems to have little effect on glucagon secretion or glucose tolerance. |
| 222 | 20805377 | Comment on: Chauhan et al. (2010) Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. |
| 223 | 20873210 | [Polymorphic markers TCF7L2 rs12255372 and SLC30A8 rs13266634 confer susceptibility to type 2 diabetes in a Russian population]. |
| 224 | 20873210 | Genes 7CF7L2 and SLC30A8, encoding transcription factor-4 and transmembrane zinc transporter-8, respectively, play an important role in the regulation of development, proliferation, and pancreatic beta cell function. |
| 225 | 20873210 | [Polymorphic markers TCF7L2 rs12255372 and SLC30A8 rs13266634 confer susceptibility to type 2 diabetes in a Russian population]. |
| 226 | 20873210 | Genes 7CF7L2 and SLC30A8, encoding transcription factor-4 and transmembrane zinc transporter-8, respectively, play an important role in the regulation of development, proliferation, and pancreatic beta cell function. |
| 227 | 20878272 | In this review we describe the progress that has been made to date in translating association signals into molecular mechanisms with a focus on the most tractable signals (eg, KCNJ11/ABCC8, SLC30A8, GCKR) and those in which human, animal, and cellular models (FTO, TCF7L2, G6PC2) have provided insights into the role in T2D pathogenesis. |
| 228 | 21067978 | The aim of this study was to evaluate the humoral autoreactivity to zinc transporter 8 (ZnT8) depending on the clinical phenotype of type 1 diabetes (T1D). |
| 229 | 21067978 | ZnT8 autoantibodies (ZnT8A) were determined by radioimmunoassay using carboxy-terminal ZnT8 constructs in 57 childhood-onset, 97 adult-onset, and 85 fulminant T1D. |
| 230 | 21067978 | These results suggest differences in the humoral autoreactivity to ZnT8 depending on the clinical phenotype, which should provide strategy for autoantibody measurement in subjects to allow early diagnosis of autoimmune T1D. |
| 231 | 21067978 | The aim of this study was to evaluate the humoral autoreactivity to zinc transporter 8 (ZnT8) depending on the clinical phenotype of type 1 diabetes (T1D). |
| 232 | 21067978 | ZnT8 autoantibodies (ZnT8A) were determined by radioimmunoassay using carboxy-terminal ZnT8 constructs in 57 childhood-onset, 97 adult-onset, and 85 fulminant T1D. |
| 233 | 21067978 | These results suggest differences in the humoral autoreactivity to ZnT8 depending on the clinical phenotype, which should provide strategy for autoantibody measurement in subjects to allow early diagnosis of autoimmune T1D. |
| 234 | 21067978 | The aim of this study was to evaluate the humoral autoreactivity to zinc transporter 8 (ZnT8) depending on the clinical phenotype of type 1 diabetes (T1D). |
| 235 | 21067978 | ZnT8 autoantibodies (ZnT8A) were determined by radioimmunoassay using carboxy-terminal ZnT8 constructs in 57 childhood-onset, 97 adult-onset, and 85 fulminant T1D. |
| 236 | 21067978 | These results suggest differences in the humoral autoreactivity to ZnT8 depending on the clinical phenotype, which should provide strategy for autoantibody measurement in subjects to allow early diagnosis of autoimmune T1D. |
| 237 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 238 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 239 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 240 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 241 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 242 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 243 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 244 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 245 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 246 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 247 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 248 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 249 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 250 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 251 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 252 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 253 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 254 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 255 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 256 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 257 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 258 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 259 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 260 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 261 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 262 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 263 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 264 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 265 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 266 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 267 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 268 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 269 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 270 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 271 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 272 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 273 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 274 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 275 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 276 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 277 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 278 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 279 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 280 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 281 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 282 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 283 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 284 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 285 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 286 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 287 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 288 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 289 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 290 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 291 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 292 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 293 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 294 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 295 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 296 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 297 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 298 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 299 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 300 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 301 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 302 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 303 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 304 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 305 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 306 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 307 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 308 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 309 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 310 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 311 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 312 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 313 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 314 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 315 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 316 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 317 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 318 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 319 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 320 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 321 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 322 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 323 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 324 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 325 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 326 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 327 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 328 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 329 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 330 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 331 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 332 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 333 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 334 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 335 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 336 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 337 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 338 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 339 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 340 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 341 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 342 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 343 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 344 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 345 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 346 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 347 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 348 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 349 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 350 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 351 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 352 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 353 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 354 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 355 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 356 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 357 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 358 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 359 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 360 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 361 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 362 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 363 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 364 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 365 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 366 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 367 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 368 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 369 | 21099260 | Downregulation of ZnT8 expression in pancreatic β-cells of diabetic mice. |
| 370 | 21099260 | Zinc transporter 8 (ZnT8) has been identified as a β-cell-specific Zinc transporter expressed in insulin-secretory granules. |
| 371 | 21099260 | Recent genome wide association studies indicated that Arg325Trp polymorphism of Slc30a8 encoding ZnT8 is associated with susceptibility to type 2 diabetes. |
| 372 | 21099260 | As a first step towards understanding the pathogenic role of ZnT8 in diabetes, we evaluated the expression of ZnT8 in mouse pancreas. |
| 373 | 21099260 | A rabbit polyclonal antibody specific to ZnT8 was raised. |
| 374 | 21099260 | The raised ZnT8 antibody reacted with mouse, rat and human ZnT8 expressed in β-cells without cross-reacting with other ZnTs. |
| 375 | 21099260 | ZnT8 was expressed in α-, β- and PP-cells, but not in δ-cells, in adult mouse islets. |
| 376 | 21099260 | During mouse pancreas development, ZnT8 expression was detected as early as embryonic day 15.5 when β-cells started to appear in large numbers. |
| 377 | 21099260 | Finally, the expression level of ZnT8 was compared with pancreas of two diabetic model mice, db/db mice and Akita mice. |
| 378 | 21099260 | In both animal models of diabetes, ZnT8 expression was remarkably downregulated in the early stage of diabetes. |
| 379 | 21099260 | As a conclusion, ZnT8 is expressed in multiple lineages of endocrine cells in the pancreas. |
| 380 | 21099260 | Our findings suggest that downregulation of ZnT8 may be associated with impaired function of β-cells in diabetes. |
| 381 | 21099294 | Genome wide association studies have identified the islet-restricted zinc transporter ZnT8 (SLC30A8) as a likely player in the control of insulin secretion and the risk of developing type 2 diabetes. |
| 382 | 21099294 | The author's laboratory and others have now developed knockout mouse models for the ZnT8 gene, and have studied the impact of the at-risk R325W polymorphism on the activity of this crucial islet zinc transporter. |
| 383 | 21099294 | Genome wide association studies have identified the islet-restricted zinc transporter ZnT8 (SLC30A8) as a likely player in the control of insulin secretion and the risk of developing type 2 diabetes. |
| 384 | 21099294 | The author's laboratory and others have now developed knockout mouse models for the ZnT8 gene, and have studied the impact of the at-risk R325W polymorphism on the activity of this crucial islet zinc transporter. |
| 385 | 21103350 | Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 are associated with glucose metabolism in the Chinese. |
| 386 | 21198374 | Worldwide researchers have invested time, effort, and money during the last years to find new genes associated with diabetes susceptibility, such as LOC387761, HHEX, EXT2, and SLC30A8. |
| 387 | 21198374 | In addition, there was no association between T2D and the SNPs of HHEX, EXT2, and SLC30A8. |
| 388 | 21198374 | Worldwide researchers have invested time, effort, and money during the last years to find new genes associated with diabetes susceptibility, such as LOC387761, HHEX, EXT2, and SLC30A8. |
| 389 | 21198374 | In addition, there was no association between T2D and the SNPs of HHEX, EXT2, and SLC30A8. |
| 390 | 21437630 | Association of type 2 diabetes susceptibility genes (TCF7L2, SLC30A8, PCSK1 and PCSK2) and proinsulin conversion in a Chinese population. |
| 391 | 21437630 | TCF7L2 and SLC30A8 have been found to be associated with type 2 diabetes mellitus (T2DM) as well as with impaired proinsulin processing recently, enzymes encoded by PCSK1 and PCSK2 are reported to play an important role in the process of proinsulin conversion. |
| 392 | 21437630 | To investigate whether the single nucleotide polymorphisms (SNPs) of TCF7L2, SLC30A8, PCSK1 and PCSK2 were associated with T2DM as well as with proinsulin conversion in a Han Chinese population from Chongqing. |
| 393 | 21437630 | A case-control study was performed in Han Chinese subjects with normal control (n=152) and T2DM (n=227), we genotyped rs7903146 and rs11196218 at TCF7L2, rs13266634 at SLC30A8, rs3811951 at PCSK1 and rs2021785 at PCSK2. |
| 394 | 21437630 | Rs13266634 at SLC30A8 had a tendency to be associated with fasting plasma levels of proinsulin (P=0.0639 in additive model). |
| 395 | 21437630 | Association of type 2 diabetes susceptibility genes (TCF7L2, SLC30A8, PCSK1 and PCSK2) and proinsulin conversion in a Chinese population. |
| 396 | 21437630 | TCF7L2 and SLC30A8 have been found to be associated with type 2 diabetes mellitus (T2DM) as well as with impaired proinsulin processing recently, enzymes encoded by PCSK1 and PCSK2 are reported to play an important role in the process of proinsulin conversion. |
| 397 | 21437630 | To investigate whether the single nucleotide polymorphisms (SNPs) of TCF7L2, SLC30A8, PCSK1 and PCSK2 were associated with T2DM as well as with proinsulin conversion in a Han Chinese population from Chongqing. |
| 398 | 21437630 | A case-control study was performed in Han Chinese subjects with normal control (n=152) and T2DM (n=227), we genotyped rs7903146 and rs11196218 at TCF7L2, rs13266634 at SLC30A8, rs3811951 at PCSK1 and rs2021785 at PCSK2. |
| 399 | 21437630 | Rs13266634 at SLC30A8 had a tendency to be associated with fasting plasma levels of proinsulin (P=0.0639 in additive model). |
| 400 | 21437630 | Association of type 2 diabetes susceptibility genes (TCF7L2, SLC30A8, PCSK1 and PCSK2) and proinsulin conversion in a Chinese population. |
| 401 | 21437630 | TCF7L2 and SLC30A8 have been found to be associated with type 2 diabetes mellitus (T2DM) as well as with impaired proinsulin processing recently, enzymes encoded by PCSK1 and PCSK2 are reported to play an important role in the process of proinsulin conversion. |
| 402 | 21437630 | To investigate whether the single nucleotide polymorphisms (SNPs) of TCF7L2, SLC30A8, PCSK1 and PCSK2 were associated with T2DM as well as with proinsulin conversion in a Han Chinese population from Chongqing. |
| 403 | 21437630 | A case-control study was performed in Han Chinese subjects with normal control (n=152) and T2DM (n=227), we genotyped rs7903146 and rs11196218 at TCF7L2, rs13266634 at SLC30A8, rs3811951 at PCSK1 and rs2021785 at PCSK2. |
| 404 | 21437630 | Rs13266634 at SLC30A8 had a tendency to be associated with fasting plasma levels of proinsulin (P=0.0639 in additive model). |
| 405 | 21437630 | Association of type 2 diabetes susceptibility genes (TCF7L2, SLC30A8, PCSK1 and PCSK2) and proinsulin conversion in a Chinese population. |
| 406 | 21437630 | TCF7L2 and SLC30A8 have been found to be associated with type 2 diabetes mellitus (T2DM) as well as with impaired proinsulin processing recently, enzymes encoded by PCSK1 and PCSK2 are reported to play an important role in the process of proinsulin conversion. |
| 407 | 21437630 | To investigate whether the single nucleotide polymorphisms (SNPs) of TCF7L2, SLC30A8, PCSK1 and PCSK2 were associated with T2DM as well as with proinsulin conversion in a Han Chinese population from Chongqing. |
| 408 | 21437630 | A case-control study was performed in Han Chinese subjects with normal control (n=152) and T2DM (n=227), we genotyped rs7903146 and rs11196218 at TCF7L2, rs13266634 at SLC30A8, rs3811951 at PCSK1 and rs2021785 at PCSK2. |
| 409 | 21437630 | Rs13266634 at SLC30A8 had a tendency to be associated with fasting plasma levels of proinsulin (P=0.0639 in additive model). |
| 410 | 21437630 | Association of type 2 diabetes susceptibility genes (TCF7L2, SLC30A8, PCSK1 and PCSK2) and proinsulin conversion in a Chinese population. |
| 411 | 21437630 | TCF7L2 and SLC30A8 have been found to be associated with type 2 diabetes mellitus (T2DM) as well as with impaired proinsulin processing recently, enzymes encoded by PCSK1 and PCSK2 are reported to play an important role in the process of proinsulin conversion. |
| 412 | 21437630 | To investigate whether the single nucleotide polymorphisms (SNPs) of TCF7L2, SLC30A8, PCSK1 and PCSK2 were associated with T2DM as well as with proinsulin conversion in a Han Chinese population from Chongqing. |
| 413 | 21437630 | A case-control study was performed in Han Chinese subjects with normal control (n=152) and T2DM (n=227), we genotyped rs7903146 and rs11196218 at TCF7L2, rs13266634 at SLC30A8, rs3811951 at PCSK1 and rs2021785 at PCSK2. |
| 414 | 21437630 | Rs13266634 at SLC30A8 had a tendency to be associated with fasting plasma levels of proinsulin (P=0.0639 in additive model). |
| 415 | 21461562 | Recent human genetic studies have revealed that common variants of the zinc transporter 8 (ZnT-8) gene are strongly associated with type 2 diabetes mellitus (T2DM). |
| 416 | 21461562 | ZnT-8 has been suggested as a potential candidate in the regulation of insulin secretion in pancreatic β-cells. |
| 417 | 21461562 | Furthermore, the effect of Exendin-4 (an analogue of glucagon-like peptide-1) on ZnT-8 expression was examined in the db/db mice. |
| 418 | 21461562 | Reduced ZnT-8 production in the pancreas may advance defects in insulin secretion in diabetes. |
| 419 | 21461562 | Recent human genetic studies have revealed that common variants of the zinc transporter 8 (ZnT-8) gene are strongly associated with type 2 diabetes mellitus (T2DM). |
| 420 | 21461562 | ZnT-8 has been suggested as a potential candidate in the regulation of insulin secretion in pancreatic β-cells. |
| 421 | 21461562 | Furthermore, the effect of Exendin-4 (an analogue of glucagon-like peptide-1) on ZnT-8 expression was examined in the db/db mice. |
| 422 | 21461562 | Reduced ZnT-8 production in the pancreas may advance defects in insulin secretion in diabetes. |
| 423 | 21461562 | Recent human genetic studies have revealed that common variants of the zinc transporter 8 (ZnT-8) gene are strongly associated with type 2 diabetes mellitus (T2DM). |
| 424 | 21461562 | ZnT-8 has been suggested as a potential candidate in the regulation of insulin secretion in pancreatic β-cells. |
| 425 | 21461562 | Furthermore, the effect of Exendin-4 (an analogue of glucagon-like peptide-1) on ZnT-8 expression was examined in the db/db mice. |
| 426 | 21461562 | Reduced ZnT-8 production in the pancreas may advance defects in insulin secretion in diabetes. |
| 427 | 21461562 | Recent human genetic studies have revealed that common variants of the zinc transporter 8 (ZnT-8) gene are strongly associated with type 2 diabetes mellitus (T2DM). |
| 428 | 21461562 | ZnT-8 has been suggested as a potential candidate in the regulation of insulin secretion in pancreatic β-cells. |
| 429 | 21461562 | Furthermore, the effect of Exendin-4 (an analogue of glucagon-like peptide-1) on ZnT-8 expression was examined in the db/db mice. |
| 430 | 21461562 | Reduced ZnT-8 production in the pancreas may advance defects in insulin secretion in diabetes. |
| 431 | 21471440 | Recently we demonstrated that zinc transporter 8 (ZnT8) is a major target of autoantibodies in human type 1 diabetes (T1D). |
| 432 | 21471440 | To test this hypothesis, IFN-γ-producing T cells specific for ZnT8 in the peripheral blood of 35 patients with T1D (<6 mo after onset at blood draw) and 41 age-matched controls were assayed by ELISPOT using a library of 23 overlapping dipeptide pools covering the entire 369 aa primary sequence. |
| 433 | 21471440 | We conclude that ZnT8 is also a major target of disease-associated autoreactive T cells in human T1D, and we suggest that reagents that target ZnT8-specific T cells could have therapeutic potential in preventing or arresting the progression of this disease. |
| 434 | 21471440 | Recently we demonstrated that zinc transporter 8 (ZnT8) is a major target of autoantibodies in human type 1 diabetes (T1D). |
| 435 | 21471440 | To test this hypothesis, IFN-γ-producing T cells specific for ZnT8 in the peripheral blood of 35 patients with T1D (<6 mo after onset at blood draw) and 41 age-matched controls were assayed by ELISPOT using a library of 23 overlapping dipeptide pools covering the entire 369 aa primary sequence. |
| 436 | 21471440 | We conclude that ZnT8 is also a major target of disease-associated autoreactive T cells in human T1D, and we suggest that reagents that target ZnT8-specific T cells could have therapeutic potential in preventing or arresting the progression of this disease. |
| 437 | 21471440 | Recently we demonstrated that zinc transporter 8 (ZnT8) is a major target of autoantibodies in human type 1 diabetes (T1D). |
| 438 | 21471440 | To test this hypothesis, IFN-γ-producing T cells specific for ZnT8 in the peripheral blood of 35 patients with T1D (<6 mo after onset at blood draw) and 41 age-matched controls were assayed by ELISPOT using a library of 23 overlapping dipeptide pools covering the entire 369 aa primary sequence. |
| 439 | 21471440 | We conclude that ZnT8 is also a major target of disease-associated autoreactive T cells in human T1D, and we suggest that reagents that target ZnT8-specific T cells could have therapeutic potential in preventing or arresting the progression of this disease. |
| 440 | 21550079 | Genotype risk score was calculated by the following variants, namely, KCNQ1, TCF7L2, CDKAL1, HHEX, IGF2BP2, CDKN2AB, SLC30A8, KCNJ11, PPARG, and GCKR. |
| 441 | 21713314 | The zinc transporter, ZnT8 is an important target for autoimmunity in type 1 diabetes. |
| 442 | 21779873 | Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program. |
| 443 | 21798992 | Genome-wide association studies have shown that a polymorphic variant in SLC30A8, which encodes zinc transporter-8, is associated with altered susceptibility to type 2 diabetes (T2D). |
| 444 | 21798992 | This association is consistent with the observation that glucose-stimulated insulin secretion is decreased in islets isolated from Slc30a8 knockout mice. |
| 445 | 21798992 | Genome-wide association studies have shown that a polymorphic variant in SLC30A8, which encodes zinc transporter-8, is associated with altered susceptibility to type 2 diabetes (T2D). |
| 446 | 21798992 | This association is consistent with the observation that glucose-stimulated insulin secretion is decreased in islets isolated from Slc30a8 knockout mice. |
| 447 | 21810599 | Total zinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: a 14-cohort meta-analysis. |
| 448 | 21821034 | Antibody staining for insulin, glucagon, somatostatin and Glucagon-like peptide-1 (GLP-1) showed that the distribution pattern of the different cell types within islets was comparable to pig and human islets. |
| 449 | 21821034 | In all three species protein expression of zinc transporter ZnT8 was detected in most of the insulin producing beta cells whereas Zip14 expression was widely expressed in alpha and beta cells. |
| 450 | 21821034 | In both human and NWP little or no expression of Glut2 was observed compared to Glut1 and glucokinase at the protein level, however the messenger RNA level of Glut2 was greater than Glut1 and glucokinase. |
| 451 | 21875382 | Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. |
| 452 | 21875382 | A total of 271 patients diagnosed for diabetes at mean age 53.4 ± 10.9, body mass index ≤ 30, without insulin treatment for the first year of disease, and initially classified as type 2 diabetic patients were tested for ZnT8A using cDNA plasmids encoding the C-terminal domains (aa 268-369) carrying 325Arg, 325Trp, and a dimeric cDNA construct carrying both 325Arg and 325Trp (ZnT8 Arg-Trp325). |
| 453 | 21875382 | We also analyzed proinsulin autoantibodies (PAA), glutamic acid decarboxylase autoantibodies (GADA), and protein tyrosine phosphatase IA-2 autoantibodies (IA-2A). |
| 454 | 21875382 | Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. |
| 455 | 21875382 | A total of 271 patients diagnosed for diabetes at mean age 53.4 ± 10.9, body mass index ≤ 30, without insulin treatment for the first year of disease, and initially classified as type 2 diabetic patients were tested for ZnT8A using cDNA plasmids encoding the C-terminal domains (aa 268-369) carrying 325Arg, 325Trp, and a dimeric cDNA construct carrying both 325Arg and 325Trp (ZnT8 Arg-Trp325). |
| 456 | 21875382 | We also analyzed proinsulin autoantibodies (PAA), glutamic acid decarboxylase autoantibodies (GADA), and protein tyrosine phosphatase IA-2 autoantibodies (IA-2A). |
| 457 | 22046415 | Antibodies recognizing Mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients. |
| 458 | 22046415 | We asked whether antibodies (Abs) against one of these proteins, namely MAP3865c, which displays a sequence homology with the β-cell protein zinc transporter 8 (ZnT8) could be cross-reactive with ZnT8 epitopes. |
| 459 | 22046415 | There was a linear correlation between titers of anti-MAP3865c and anti-ZnT8 Abs targeting these two homologous epitopes, and pre-incubation of sera with ZnT8 epitope peptides blocked binding to the corresponding MAP3865c peptides. |
| 460 | 22046415 | These results demonstrate that Abs recognizing MAP3865c epitopes cross-react with ZnT8, possibly underlying a molecular mimicry mechanism, which may precipitate T1D in MAP-infected individuals. |
| 461 | 22046415 | Antibodies recognizing Mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients. |
| 462 | 22046415 | We asked whether antibodies (Abs) against one of these proteins, namely MAP3865c, which displays a sequence homology with the β-cell protein zinc transporter 8 (ZnT8) could be cross-reactive with ZnT8 epitopes. |
| 463 | 22046415 | There was a linear correlation between titers of anti-MAP3865c and anti-ZnT8 Abs targeting these two homologous epitopes, and pre-incubation of sera with ZnT8 epitope peptides blocked binding to the corresponding MAP3865c peptides. |
| 464 | 22046415 | These results demonstrate that Abs recognizing MAP3865c epitopes cross-react with ZnT8, possibly underlying a molecular mimicry mechanism, which may precipitate T1D in MAP-infected individuals. |
| 465 | 22046415 | Antibodies recognizing Mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients. |
| 466 | 22046415 | We asked whether antibodies (Abs) against one of these proteins, namely MAP3865c, which displays a sequence homology with the β-cell protein zinc transporter 8 (ZnT8) could be cross-reactive with ZnT8 epitopes. |
| 467 | 22046415 | There was a linear correlation between titers of anti-MAP3865c and anti-ZnT8 Abs targeting these two homologous epitopes, and pre-incubation of sera with ZnT8 epitope peptides blocked binding to the corresponding MAP3865c peptides. |
| 468 | 22046415 | These results demonstrate that Abs recognizing MAP3865c epitopes cross-react with ZnT8, possibly underlying a molecular mimicry mechanism, which may precipitate T1D in MAP-infected individuals. |
| 469 | 22046415 | Antibodies recognizing Mycobacterium avium paratuberculosis epitopes cross-react with the beta-cell antigen ZnT8 in Sardinian type 1 diabetic patients. |
| 470 | 22046415 | We asked whether antibodies (Abs) against one of these proteins, namely MAP3865c, which displays a sequence homology with the β-cell protein zinc transporter 8 (ZnT8) could be cross-reactive with ZnT8 epitopes. |
| 471 | 22046415 | There was a linear correlation between titers of anti-MAP3865c and anti-ZnT8 Abs targeting these two homologous epitopes, and pre-incubation of sera with ZnT8 epitope peptides blocked binding to the corresponding MAP3865c peptides. |
| 472 | 22046415 | These results demonstrate that Abs recognizing MAP3865c epitopes cross-react with ZnT8, possibly underlying a molecular mimicry mechanism, which may precipitate T1D in MAP-infected individuals. |
| 473 | 22069259 | ZnT8 and chromogranin A, has taught us that we still have much to learn about the targets of the autoimmune response in type 1 diabetes. |
| 474 | 22260783 | Zinc transporter-8 (ZnT8) has emerged in recent years as a novel, major, human autoantigen. |
| 475 | 22260783 | Therefore, we aim to identify the HLA-A2-restricted ZnT8 epitopes using both binding and dissociation assays. |
| 476 | 22260783 | HLA class I peptide affinity algorithms were used to predict candidate ZnT8 peptides that bind to HLA-A2. |
| 477 | 22260783 | We analyzed 15 reported epitopes of seven β-cell candidate autoantigens and eight predicted candidate ZnT8 peptides using binding and dissociation assays. |
| 478 | 22260783 | Using IFN-γ ELISpot assay, we tested peripheral blood mononuclear cells (PBMCs) from recent-onset T1D patients and healthy controls for reactivity to seven reported epitopes and eight candidate ZnT8 peptides directly ex vivo. |
| 479 | 22260783 | Of the eight predicted ZnT8 peptides, ZnT8(153-161) had a strong binding affinity and the lowest dissociation rate to HLA-A*0201. |
| 480 | 22260783 | We conclude that ZnT8(153-161) is a novel HLA-A*0201-restricted T-cell epitope. |
| 481 | 22260783 | Zinc transporter-8 (ZnT8) has emerged in recent years as a novel, major, human autoantigen. |
| 482 | 22260783 | Therefore, we aim to identify the HLA-A2-restricted ZnT8 epitopes using both binding and dissociation assays. |
| 483 | 22260783 | HLA class I peptide affinity algorithms were used to predict candidate ZnT8 peptides that bind to HLA-A2. |
| 484 | 22260783 | We analyzed 15 reported epitopes of seven β-cell candidate autoantigens and eight predicted candidate ZnT8 peptides using binding and dissociation assays. |
| 485 | 22260783 | Using IFN-γ ELISpot assay, we tested peripheral blood mononuclear cells (PBMCs) from recent-onset T1D patients and healthy controls for reactivity to seven reported epitopes and eight candidate ZnT8 peptides directly ex vivo. |
| 486 | 22260783 | Of the eight predicted ZnT8 peptides, ZnT8(153-161) had a strong binding affinity and the lowest dissociation rate to HLA-A*0201. |
| 487 | 22260783 | We conclude that ZnT8(153-161) is a novel HLA-A*0201-restricted T-cell epitope. |
| 488 | 22260783 | Zinc transporter-8 (ZnT8) has emerged in recent years as a novel, major, human autoantigen. |
| 489 | 22260783 | Therefore, we aim to identify the HLA-A2-restricted ZnT8 epitopes using both binding and dissociation assays. |
| 490 | 22260783 | HLA class I peptide affinity algorithms were used to predict candidate ZnT8 peptides that bind to HLA-A2. |
| 491 | 22260783 | We analyzed 15 reported epitopes of seven β-cell candidate autoantigens and eight predicted candidate ZnT8 peptides using binding and dissociation assays. |
| 492 | 22260783 | Using IFN-γ ELISpot assay, we tested peripheral blood mononuclear cells (PBMCs) from recent-onset T1D patients and healthy controls for reactivity to seven reported epitopes and eight candidate ZnT8 peptides directly ex vivo. |
| 493 | 22260783 | Of the eight predicted ZnT8 peptides, ZnT8(153-161) had a strong binding affinity and the lowest dissociation rate to HLA-A*0201. |
| 494 | 22260783 | We conclude that ZnT8(153-161) is a novel HLA-A*0201-restricted T-cell epitope. |
| 495 | 22260783 | Zinc transporter-8 (ZnT8) has emerged in recent years as a novel, major, human autoantigen. |
| 496 | 22260783 | Therefore, we aim to identify the HLA-A2-restricted ZnT8 epitopes using both binding and dissociation assays. |
| 497 | 22260783 | HLA class I peptide affinity algorithms were used to predict candidate ZnT8 peptides that bind to HLA-A2. |
| 498 | 22260783 | We analyzed 15 reported epitopes of seven β-cell candidate autoantigens and eight predicted candidate ZnT8 peptides using binding and dissociation assays. |
| 499 | 22260783 | Using IFN-γ ELISpot assay, we tested peripheral blood mononuclear cells (PBMCs) from recent-onset T1D patients and healthy controls for reactivity to seven reported epitopes and eight candidate ZnT8 peptides directly ex vivo. |
| 500 | 22260783 | Of the eight predicted ZnT8 peptides, ZnT8(153-161) had a strong binding affinity and the lowest dissociation rate to HLA-A*0201. |
| 501 | 22260783 | We conclude that ZnT8(153-161) is a novel HLA-A*0201-restricted T-cell epitope. |
| 502 | 22260783 | Zinc transporter-8 (ZnT8) has emerged in recent years as a novel, major, human autoantigen. |
| 503 | 22260783 | Therefore, we aim to identify the HLA-A2-restricted ZnT8 epitopes using both binding and dissociation assays. |
| 504 | 22260783 | HLA class I peptide affinity algorithms were used to predict candidate ZnT8 peptides that bind to HLA-A2. |
| 505 | 22260783 | We analyzed 15 reported epitopes of seven β-cell candidate autoantigens and eight predicted candidate ZnT8 peptides using binding and dissociation assays. |
| 506 | 22260783 | Using IFN-γ ELISpot assay, we tested peripheral blood mononuclear cells (PBMCs) from recent-onset T1D patients and healthy controls for reactivity to seven reported epitopes and eight candidate ZnT8 peptides directly ex vivo. |
| 507 | 22260783 | Of the eight predicted ZnT8 peptides, ZnT8(153-161) had a strong binding affinity and the lowest dissociation rate to HLA-A*0201. |
| 508 | 22260783 | We conclude that ZnT8(153-161) is a novel HLA-A*0201-restricted T-cell epitope. |
| 509 | 22260783 | Zinc transporter-8 (ZnT8) has emerged in recent years as a novel, major, human autoantigen. |
| 510 | 22260783 | Therefore, we aim to identify the HLA-A2-restricted ZnT8 epitopes using both binding and dissociation assays. |
| 511 | 22260783 | HLA class I peptide affinity algorithms were used to predict candidate ZnT8 peptides that bind to HLA-A2. |
| 512 | 22260783 | We analyzed 15 reported epitopes of seven β-cell candidate autoantigens and eight predicted candidate ZnT8 peptides using binding and dissociation assays. |
| 513 | 22260783 | Using IFN-γ ELISpot assay, we tested peripheral blood mononuclear cells (PBMCs) from recent-onset T1D patients and healthy controls for reactivity to seven reported epitopes and eight candidate ZnT8 peptides directly ex vivo. |
| 514 | 22260783 | Of the eight predicted ZnT8 peptides, ZnT8(153-161) had a strong binding affinity and the lowest dissociation rate to HLA-A*0201. |
| 515 | 22260783 | We conclude that ZnT8(153-161) is a novel HLA-A*0201-restricted T-cell epitope. |
| 516 | 22260783 | Zinc transporter-8 (ZnT8) has emerged in recent years as a novel, major, human autoantigen. |
| 517 | 22260783 | Therefore, we aim to identify the HLA-A2-restricted ZnT8 epitopes using both binding and dissociation assays. |
| 518 | 22260783 | HLA class I peptide affinity algorithms were used to predict candidate ZnT8 peptides that bind to HLA-A2. |
| 519 | 22260783 | We analyzed 15 reported epitopes of seven β-cell candidate autoantigens and eight predicted candidate ZnT8 peptides using binding and dissociation assays. |
| 520 | 22260783 | Using IFN-γ ELISpot assay, we tested peripheral blood mononuclear cells (PBMCs) from recent-onset T1D patients and healthy controls for reactivity to seven reported epitopes and eight candidate ZnT8 peptides directly ex vivo. |
| 521 | 22260783 | Of the eight predicted ZnT8 peptides, ZnT8(153-161) had a strong binding affinity and the lowest dissociation rate to HLA-A*0201. |
| 522 | 22260783 | We conclude that ZnT8(153-161) is a novel HLA-A*0201-restricted T-cell epitope. |
| 523 | 22402369 | To further characterize the association between zinc and diabetes, we recruited 75 patients with type 1 or type 2 diabetes and 75 nondiabetic sex-/age-matched control subjects in order to analyze differences concerning human zinc transporter 8 (hZnT-8) expression, single nucleotide polymorphisms (SNPs) in the genes of hZnT-8 as well as metallothionein 1A and serum/intracellular zinc. |
| 524 | 22443257 | Polycystic ovary syndrome is not associated with polymorphisms of the TCF7L2, CDKAL1, HHEX, KCNJ11, FTO and SLC30A8 genes. |
| 525 | 22447136 | Furthermore, humoral autoreactivity to ZnT8 is unique in terms of a key determinant, which is not reported on other islet autoantigens such as insulin, glutamic acid decarboxylase, or the protein tyrosine phosphatase-related molecules IA-2. |
| 526 | 22487833 | [Association analysis of genetic polymorphisms of TCF7L2, CDKAL1, SLC30A8, HHEX genes and microvascular complications of type 2 diabetes mellitus]. |
| 527 | 22526605 | Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases. |
| 528 | 22526607 | Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients. |
| 529 | 22528778 | Plasma zinc concentrations and zinc transporter (ZnT1, ZnT8, and Zip1) gene expression in mononuclear cells were measured. |
| 530 | 22567309 | The importance of the cellular immune reaction involving cytotoxic CD8-positive T cells to kill beta cells through Class I MHC is discussed along with speculations of the possible role of B lymphocytes in presenting the proinsulin autoantigen over and over again through insulin-carrying insulin autoantibodies. |
| 531 | 22567309 | In contrast to autoantibodies against other islet autoantigens such as GAD65, IA-2, and ZnT8 transporters, it has not been possible yet to standardize the insulin autoantibody test. |
| 532 | 22582094 | Both zinc depletion and lipotoxicity (but not glucotoxicity) downregulated ZNT8 (SLC30A8) expression and altered the glucose-stimulated insulin secretion index (GSIS). |
| 533 | 22582094 | Altogether, we showed that ZNT8 expression responds to variation in zinc and lipid levels in human β cells, with repercussions on insulin secretion. |
| 534 | 22582094 | Both zinc depletion and lipotoxicity (but not glucotoxicity) downregulated ZNT8 (SLC30A8) expression and altered the glucose-stimulated insulin secretion index (GSIS). |
| 535 | 22582094 | Altogether, we showed that ZNT8 expression responds to variation in zinc and lipid levels in human β cells, with repercussions on insulin secretion. |
| 536 | 22586580 | ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. |
| 537 | 22586580 | The objective of this study was twofold: 1) to develop a CD8(+) T-cell interferon-γ ELISpot assay for pediatric patients and 2) to determine whether zinc transporter 8 (ZnT8), a recently described target of autoantibodies in a majority of patients, is also recognized by autoreactive CD8(+) T cells. |
| 538 | 22586580 | Using DNA immunization of humanized mice, we identified nine HLA-A2-restricted ZnT8 epitopes. |
| 539 | 22586580 | Among 36 HLA-A2(+) children with diabetes, 29 responded to ZnT8 epitopes, whereas only 3 of 16 HLA-A2(+) control patients and 0 of 17 HLA-A2(-) control patients responded. |
| 540 | 22586580 | Some single ZnT8 epitopes performed as well as the group of epitopes in discriminating between patients and control individuals. |
| 541 | 22586580 | Thus, ZnT8 is a major CD8(+) T-cell autoantigen, and ELISpot assays display similar performance in adult and pediatric type 1 diabetes. |
| 542 | 22586580 | ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. |
| 543 | 22586580 | The objective of this study was twofold: 1) to develop a CD8(+) T-cell interferon-γ ELISpot assay for pediatric patients and 2) to determine whether zinc transporter 8 (ZnT8), a recently described target of autoantibodies in a majority of patients, is also recognized by autoreactive CD8(+) T cells. |
| 544 | 22586580 | Using DNA immunization of humanized mice, we identified nine HLA-A2-restricted ZnT8 epitopes. |
| 545 | 22586580 | Among 36 HLA-A2(+) children with diabetes, 29 responded to ZnT8 epitopes, whereas only 3 of 16 HLA-A2(+) control patients and 0 of 17 HLA-A2(-) control patients responded. |
| 546 | 22586580 | Some single ZnT8 epitopes performed as well as the group of epitopes in discriminating between patients and control individuals. |
| 547 | 22586580 | Thus, ZnT8 is a major CD8(+) T-cell autoantigen, and ELISpot assays display similar performance in adult and pediatric type 1 diabetes. |
| 548 | 22586580 | ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. |
| 549 | 22586580 | The objective of this study was twofold: 1) to develop a CD8(+) T-cell interferon-γ ELISpot assay for pediatric patients and 2) to determine whether zinc transporter 8 (ZnT8), a recently described target of autoantibodies in a majority of patients, is also recognized by autoreactive CD8(+) T cells. |
| 550 | 22586580 | Using DNA immunization of humanized mice, we identified nine HLA-A2-restricted ZnT8 epitopes. |
| 551 | 22586580 | Among 36 HLA-A2(+) children with diabetes, 29 responded to ZnT8 epitopes, whereas only 3 of 16 HLA-A2(+) control patients and 0 of 17 HLA-A2(-) control patients responded. |
| 552 | 22586580 | Some single ZnT8 epitopes performed as well as the group of epitopes in discriminating between patients and control individuals. |
| 553 | 22586580 | Thus, ZnT8 is a major CD8(+) T-cell autoantigen, and ELISpot assays display similar performance in adult and pediatric type 1 diabetes. |
| 554 | 22586580 | ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. |
| 555 | 22586580 | The objective of this study was twofold: 1) to develop a CD8(+) T-cell interferon-γ ELISpot assay for pediatric patients and 2) to determine whether zinc transporter 8 (ZnT8), a recently described target of autoantibodies in a majority of patients, is also recognized by autoreactive CD8(+) T cells. |
| 556 | 22586580 | Using DNA immunization of humanized mice, we identified nine HLA-A2-restricted ZnT8 epitopes. |
| 557 | 22586580 | Among 36 HLA-A2(+) children with diabetes, 29 responded to ZnT8 epitopes, whereas only 3 of 16 HLA-A2(+) control patients and 0 of 17 HLA-A2(-) control patients responded. |
| 558 | 22586580 | Some single ZnT8 epitopes performed as well as the group of epitopes in discriminating between patients and control individuals. |
| 559 | 22586580 | Thus, ZnT8 is a major CD8(+) T-cell autoantigen, and ELISpot assays display similar performance in adult and pediatric type 1 diabetes. |
| 560 | 22586580 | ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. |
| 561 | 22586580 | The objective of this study was twofold: 1) to develop a CD8(+) T-cell interferon-γ ELISpot assay for pediatric patients and 2) to determine whether zinc transporter 8 (ZnT8), a recently described target of autoantibodies in a majority of patients, is also recognized by autoreactive CD8(+) T cells. |
| 562 | 22586580 | Using DNA immunization of humanized mice, we identified nine HLA-A2-restricted ZnT8 epitopes. |
| 563 | 22586580 | Among 36 HLA-A2(+) children with diabetes, 29 responded to ZnT8 epitopes, whereas only 3 of 16 HLA-A2(+) control patients and 0 of 17 HLA-A2(-) control patients responded. |
| 564 | 22586580 | Some single ZnT8 epitopes performed as well as the group of epitopes in discriminating between patients and control individuals. |
| 565 | 22586580 | Thus, ZnT8 is a major CD8(+) T-cell autoantigen, and ELISpot assays display similar performance in adult and pediatric type 1 diabetes. |
| 566 | 22586580 | ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. |
| 567 | 22586580 | The objective of this study was twofold: 1) to develop a CD8(+) T-cell interferon-γ ELISpot assay for pediatric patients and 2) to determine whether zinc transporter 8 (ZnT8), a recently described target of autoantibodies in a majority of patients, is also recognized by autoreactive CD8(+) T cells. |
| 568 | 22586580 | Using DNA immunization of humanized mice, we identified nine HLA-A2-restricted ZnT8 epitopes. |
| 569 | 22586580 | Among 36 HLA-A2(+) children with diabetes, 29 responded to ZnT8 epitopes, whereas only 3 of 16 HLA-A2(+) control patients and 0 of 17 HLA-A2(-) control patients responded. |
| 570 | 22586580 | Some single ZnT8 epitopes performed as well as the group of epitopes in discriminating between patients and control individuals. |
| 571 | 22586580 | Thus, ZnT8 is a major CD8(+) T-cell autoantigen, and ELISpot assays display similar performance in adult and pediatric type 1 diabetes. |
| 572 | 22686132 | Association between autoantibodies to the Arginine variant of the Zinc transporter 8 (ZnT8) and stimulated C-peptide levels in Danish children and adolescents with newly diagnosed type 1 diabetes. |
| 573 | 22749234 | Contribution of common variants of ENPP1, IGF2BP2, KCNJ11, MLXIPL, PPARγ, SLC30A8 and TCF7L2 to the risk of type 2 diabetes in Lebanese and Tunisian Arabs. |
| 574 | 22787139 | Zinc transporter 8 autoantibodies and their association with SLC30A8 and HLA-DQ genes differ between immigrant and Swedish patients with newly diagnosed type 1 diabetes in the Better Diabetes Diagnosis study. |
| 575 | 22787139 | We examined whether zinc transporter 8 autoantibodies (ZnT8A; arginine ZnT8-RA, tryptophan ZnT8-WA, and glutamine ZnT8-QA variants) differed between immigrant and Swedish patients due to different polymorphisms of SLC30A8, HLA-DQ, or both. |
| 576 | 22787139 | Zinc transporter 8 autoantibodies and their association with SLC30A8 and HLA-DQ genes differ between immigrant and Swedish patients with newly diagnosed type 1 diabetes in the Better Diabetes Diagnosis study. |
| 577 | 22787139 | We examined whether zinc transporter 8 autoantibodies (ZnT8A; arginine ZnT8-RA, tryptophan ZnT8-WA, and glutamine ZnT8-QA variants) differed between immigrant and Swedish patients due to different polymorphisms of SLC30A8, HLA-DQ, or both. |
| 578 | 22829903 | The physiological effects of deleting the mouse SLC30A8 gene encoding zinc transporter-8 are influenced by gender and genetic background. |
| 579 | 22908193 | In this context, we evaluate the biochemical nature and immunogenicity of the major autoantigens in T1D including (pro)insulin, GAD65, ZnT8, IA2, and ICA69. |
| 580 | 22923468 | Twenty-four single nucleotide polymorphisms (SNPs) in or near genes (KCNJ11, PPARG, TCF7L2, SLC30A8, HHEX, CDKN2A/2B, CDKAL1, IGF2BP2, ARHGEF11, JAZF1, CDC123/CAMK1D, FTO, TSPAN8/LGR5, KCNQ1, THADA, ADAMTS9, NOTCH2, NXPH1, RORA, UBQLNL, and RALGPS2) were genotyped in Mexican Mestizos. |
| 581 | 22923468 | Association to type 2 diabetes was found for rs13266634 (SLC30A8), rs7923837 (HHEX), rs10811661 (CDKN2A/2B), rs4402960 (IGF2BP2), rs12779790 (CDC123/CAMK1D), and rs2237892 (KCNQ1). |
| 582 | 22923468 | In addition, rs7754840 (CDKAL1) was associated in the nonobese type 2 diabetic subgroup, and for rs7903146 (TCF7L2), association was observed for early-onset type 2 diabetes. |
| 583 | 22923468 | Twenty-four single nucleotide polymorphisms (SNPs) in or near genes (KCNJ11, PPARG, TCF7L2, SLC30A8, HHEX, CDKN2A/2B, CDKAL1, IGF2BP2, ARHGEF11, JAZF1, CDC123/CAMK1D, FTO, TSPAN8/LGR5, KCNQ1, THADA, ADAMTS9, NOTCH2, NXPH1, RORA, UBQLNL, and RALGPS2) were genotyped in Mexican Mestizos. |
| 584 | 22923468 | Association to type 2 diabetes was found for rs13266634 (SLC30A8), rs7923837 (HHEX), rs10811661 (CDKN2A/2B), rs4402960 (IGF2BP2), rs12779790 (CDC123/CAMK1D), and rs2237892 (KCNQ1). |
| 585 | 22923468 | In addition, rs7754840 (CDKAL1) was associated in the nonobese type 2 diabetic subgroup, and for rs7903146 (TCF7L2), association was observed for early-onset type 2 diabetes. |
| 586 | 23018631 | These genes belong to three major classes: genes involved in drug metabolism and transporters that influence pharmacokinetics (including the cytochrome P450 [CYP] superfamily, the organic anion transporting polypeptide [OATP] family, and the polyspecific organic cation transporter [OCT] family); genes encoding drug targets and receptors (including peroxisome proliferator-activated receptor gamma [PPARG], the adenosine triphosphate [ATP]-sensitive potassium channel [K(ATP)], and incretin receptors); and genes involved in the causal pathway of T2DM that are able to modify the effects of drugs (including adipokines, transcription factor 7-like 2 (T cell specific, HMG-box) [TCF7L2], insulin receptor substrate 1 [IRS1], nitric oxide synthase 1 (neuronal) adaptor protein [NOS1AP], and solute carrier family 30 (zinc transporter), member 8 [SLC30A8]). |
| 587 | 23018631 | In addition to these three major classes, we also review the available evidence on novel genes (CDK5 regulatory subunit associated protein 1-like 1 [CDKAL1], insulin-like growth factor 2 mRNA binding protein 2 [IGF2BP2], potassium voltage-gated channel, KQT-like subfamily, member 1 [KCNQ1], paired box 4 [PAX4] and neuronal differentiation 1 [NEUROD1] transcription factors, ataxia telangiectasia mutated [ATM], and serine racemase [SRR]) that have recently been proposed as possible modulators of therapeutic response in subjects with T2DM. |
| 588 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 589 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 590 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 591 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 592 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 593 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 594 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 595 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 596 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 597 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 598 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 599 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 600 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 601 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 602 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 603 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 604 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 605 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 606 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 607 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 608 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 609 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 610 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 611 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 612 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 613 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 614 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 615 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 616 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 617 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 618 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 619 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 620 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 621 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 622 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 623 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 624 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 625 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 626 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 627 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 628 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 629 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 630 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 631 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 632 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 633 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 634 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 635 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 636 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 637 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 638 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 639 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 640 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 641 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 642 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 643 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 644 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 645 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 646 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 647 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 648 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 649 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 650 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 651 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 652 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 653 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 654 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 655 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 656 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 657 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 658 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 659 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 660 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 661 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 662 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 663 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 664 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 665 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 666 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 667 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 668 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 669 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 670 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 671 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 672 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 673 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 674 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 675 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 676 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 677 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 678 | 23209723 | Zinc transporter 8 (ZnT8) expression is reduced by ischemic insults: a potential therapeutic target to prevent ischemic retinopathy. |
| 679 | 23209723 | The zinc (Zn(++)) transporter ZnT8 plays a crucial role in zinc homeostasis. |
| 680 | 23209723 | It's been reported that an acute decrease in ZnT8 levels impairs β cell function and Zn(++) homeostasis, which contribute to the pathophysiology of diabetes mellitus (DM). |
| 681 | 23209723 | Although ZnT8 expression has been detected in the retinal pigment epithelium (RPE), its expression profile in the retina has yet to be determined. |
| 682 | 23209723 | Our aims were to; investigate the expression profile of ZnT8 in the retina; address the influence of ischemia on such expression; and evaluate the influence of YC-1; (3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole), a hypoxia inducible factor-1 (HIF-1) inhibitor, on the status of ZnT8 expression. |
| 683 | 23209723 | We used real-time RT-PCR, immunohistochemistry, and Western blot in the mouse model of oxygen-induced retinopathy (OIR) and Müller cells to evaluate the effects of ischemia/hypoxia and YC-1 on ZnT8 expression. |
| 684 | 23209723 | Our data indicate that ZnT8 was strongly expressed in the outer nuclear layer (ONL), outer plexiform layer (OPL), ganglion cell layer (GCL), and nerve fiber layer (NFL), whereas the photoreceptor layer (PRL), inner nuclear layer (INL) and inner plexiform layer (IPL) showed moderate ZnT8 immunoreactivity. |
| 685 | 23209723 | Furthermore, we demonstrate that retinal ischemic insult induces a significant downregulation of ZnT8 at the message and protein levels, YC-1 rescues the injured retina by restoring the ZnT8 to its basal homeostatic levels in the neovascular retinas. |
| 686 | 23209723 | Our data indicate that ischemic retinopathy maybe mediated by aberrant Zn(++) homeostasis caused by ZnT8 downregulation, whereas YC-1 plays a neuroprotective role against ischemic insult. |
| 687 | 23209723 | Therefore, targeting ZnT8 provides a therapeutic strategy to combat neovascular eye diseases. |
| 688 | 23246542 | Identification of novel HLA-A 0201-restricted cytotoxic T lymphocyte epitopes from Zinc Transporter 8. |
| 689 | 23246542 | Zinc Transporter 8 (ZnT8) has emerged in recent years as a target of disease-associated autoreactive T cells in human T1D. |
| 690 | 23246542 | However, ZnT8-associated CTL specific-peptides have not been identified. |
| 691 | 23246542 | In this study, we predicted and identified HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) epitopes derived from ZnT8, and utilized it to immunize HLA-A2.1/Kb transgenic (Tg) mice. |
| 692 | 23246542 | The results demonstrated that peptides of ZnT8 containing residues 107-115, 115-123 and 145-153 could elicit specific CTLs in vitro, and induce diabetes in mice. |
| 693 | 23246542 | Identification of novel HLA-A 0201-restricted cytotoxic T lymphocyte epitopes from Zinc Transporter 8. |
| 694 | 23246542 | Zinc Transporter 8 (ZnT8) has emerged in recent years as a target of disease-associated autoreactive T cells in human T1D. |
| 695 | 23246542 | However, ZnT8-associated CTL specific-peptides have not been identified. |
| 696 | 23246542 | In this study, we predicted and identified HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) epitopes derived from ZnT8, and utilized it to immunize HLA-A2.1/Kb transgenic (Tg) mice. |
| 697 | 23246542 | The results demonstrated that peptides of ZnT8 containing residues 107-115, 115-123 and 145-153 could elicit specific CTLs in vitro, and induce diabetes in mice. |
| 698 | 23246542 | Identification of novel HLA-A 0201-restricted cytotoxic T lymphocyte epitopes from Zinc Transporter 8. |
| 699 | 23246542 | Zinc Transporter 8 (ZnT8) has emerged in recent years as a target of disease-associated autoreactive T cells in human T1D. |
| 700 | 23246542 | However, ZnT8-associated CTL specific-peptides have not been identified. |
| 701 | 23246542 | In this study, we predicted and identified HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) epitopes derived from ZnT8, and utilized it to immunize HLA-A2.1/Kb transgenic (Tg) mice. |
| 702 | 23246542 | The results demonstrated that peptides of ZnT8 containing residues 107-115, 115-123 and 145-153 could elicit specific CTLs in vitro, and induce diabetes in mice. |
| 703 | 23246542 | Identification of novel HLA-A 0201-restricted cytotoxic T lymphocyte epitopes from Zinc Transporter 8. |
| 704 | 23246542 | Zinc Transporter 8 (ZnT8) has emerged in recent years as a target of disease-associated autoreactive T cells in human T1D. |
| 705 | 23246542 | However, ZnT8-associated CTL specific-peptides have not been identified. |
| 706 | 23246542 | In this study, we predicted and identified HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) epitopes derived from ZnT8, and utilized it to immunize HLA-A2.1/Kb transgenic (Tg) mice. |
| 707 | 23246542 | The results demonstrated that peptides of ZnT8 containing residues 107-115, 115-123 and 145-153 could elicit specific CTLs in vitro, and induce diabetes in mice. |
| 708 | 23296174 | Autoantibodies against insulin, GAD65, IA-2 or the ZnT8 transporter mark islet autoimmunity. |
| 709 | 23396399 | Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A*24 alleles at the onset of type 1 diabetes. |
| 710 | 23396399 | The HLA-A*24 allele has shown negative associations with autoantibodies to islet antigen-2 (IA-2) and zinc transporter 8 (ZnT8) in patients with established type 1 diabetes. |
| 711 | 23396399 | HLA-A*24 genotype and autoantibody responses to insulin (IAA), glutamate decarboxylase (GADA), IA-2, IA-2β, and ZnT8 were analyzed in samples collected from patients with recent-onset type 1 diabetes. |
| 712 | 23396399 | Antibodies targeting the protein tyrosine phosphatase domains of IA-2 and IA-2β, but not the IA-2 juxtamembrane region, were less common in patients carrying HLA-A*24 alleles. |
| 713 | 23396399 | The prevalence of ZnT8A specific or cross-reactive with the ZnT8 tryptophan-325 polymorphic residue, but not those specific to arginine-325, was reduced in HLA-A*24-positive patients. |
| 714 | 23396399 | Association of an HLA class I susceptibility allele with altered islet autoantibody phenotype at diagnosis suggests CD8 T-cell and/or natural killer cell-mediated killing modulates humoral autoimmune responses. |
| 715 | 23396399 | Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A*24 alleles at the onset of type 1 diabetes. |
| 716 | 23396399 | The HLA-A*24 allele has shown negative associations with autoantibodies to islet antigen-2 (IA-2) and zinc transporter 8 (ZnT8) in patients with established type 1 diabetes. |
| 717 | 23396399 | HLA-A*24 genotype and autoantibody responses to insulin (IAA), glutamate decarboxylase (GADA), IA-2, IA-2β, and ZnT8 were analyzed in samples collected from patients with recent-onset type 1 diabetes. |
| 718 | 23396399 | Antibodies targeting the protein tyrosine phosphatase domains of IA-2 and IA-2β, but not the IA-2 juxtamembrane region, were less common in patients carrying HLA-A*24 alleles. |
| 719 | 23396399 | The prevalence of ZnT8A specific or cross-reactive with the ZnT8 tryptophan-325 polymorphic residue, but not those specific to arginine-325, was reduced in HLA-A*24-positive patients. |
| 720 | 23396399 | Association of an HLA class I susceptibility allele with altered islet autoantibody phenotype at diagnosis suggests CD8 T-cell and/or natural killer cell-mediated killing modulates humoral autoimmune responses. |
| 721 | 23396399 | Humoral responses to islet antigen-2 and zinc transporter 8 are attenuated in patients carrying HLA-A*24 alleles at the onset of type 1 diabetes. |
| 722 | 23396399 | The HLA-A*24 allele has shown negative associations with autoantibodies to islet antigen-2 (IA-2) and zinc transporter 8 (ZnT8) in patients with established type 1 diabetes. |
| 723 | 23396399 | HLA-A*24 genotype and autoantibody responses to insulin (IAA), glutamate decarboxylase (GADA), IA-2, IA-2β, and ZnT8 were analyzed in samples collected from patients with recent-onset type 1 diabetes. |
| 724 | 23396399 | Antibodies targeting the protein tyrosine phosphatase domains of IA-2 and IA-2β, but not the IA-2 juxtamembrane region, were less common in patients carrying HLA-A*24 alleles. |
| 725 | 23396399 | The prevalence of ZnT8A specific or cross-reactive with the ZnT8 tryptophan-325 polymorphic residue, but not those specific to arginine-325, was reduced in HLA-A*24-positive patients. |
| 726 | 23396399 | Association of an HLA class I susceptibility allele with altered islet autoantibody phenotype at diagnosis suggests CD8 T-cell and/or natural killer cell-mediated killing modulates humoral autoimmune responses. |
| 727 | 23458876 | Meanwhile PPARG-2 Pro12Ala, CDKN2A/2B rs10811661, IGF2BP2 rs4402960, HHEX rs7923837, CDKAL1 rs7754840, EXT2 rs1113132 and SLC30A8 rs13266634 were found to have no significant association with T2D among Arabs. |
| 728 | 23535193 | ZnT8 antibodies in patients with cystic fibrosis: an expression of secondary beta-cell damage? |
| 729 | 23535193 | Ninety subjects with cystic fibrosis (CF) were tested for glucose tolerance and autoantibodies against insulin (IAA), glutamic acid decarboxylase (GADA), protein tyrosine phosphatase (IA2) and zinc transporter 8 (Znt8A). |
| 730 | 23710470 | Whilst mouse models have in the past been central to understanding the mechanisms through which more penetrant risk genes for T2D, for example, those responsible for neonatal or maturity-onset diabetes of the young, only a few of those identified by GWAS, notably TCF7L2 and ZnT8/SLC30A8, have to date been examined in mouse models. |
| 731 | 23724162 | Type 1 diabetes mellitus (T1DM) is characterized by recognition of beta cell proteins as self-antigens, called autoantigens (AAgs), by patients' own CD4+ and CD8+ T cells and/or the products of self-reactive B cells, called autoantibodies. |
| 732 | 23724162 | Since many excellent reviews have covered the previously identified T1DM-associated AAgs exhaustedly, here we only focus on several recently discovered T1DM-AAgs (PDX1, ZnT8, CHGA, and IAAP). |
| 733 | 23755131 | The model consists of two components: (1) A pattern of declining residual β-cell function positively associated with young age, presence of diabetic ketoacidosis and long duration of disease symptoms (P = 0.0004), and with risk alleles of WFS1, CDKN2A/2B and RNLS (P = 0.006). (2) A second pattern of high ZnT8 autoantibody levels and low postprandial glucagon levels associated with risk alleles of IFIH1, TCF2, TAF5L, IL2RA and PTPN2 and protective alleles of ERBB3 gene (P = 0.0005). |
| 734 | 23828045 | At 1 week after multiple low-dose STZ administrations, pancreatic β-cells showed impaired insulin expression, while maintaining expression of nuclear Nkx6.1. |
| 735 | 23828045 | This was accompanied by significant upregulation of p53-responsive genes in islets, including a mediator of cell cycle arrest, p21 (also known as Waf1 and Cip1). |
| 736 | 23828045 | STZ treatment also suppressed expression of a wide range of genes linked with key β-cell functions or diabetes development, such as G6pc2, Slc2a2 (Glut2), Slc30a8, Neurod1, Ucn3, Gad1, Isl1, Foxa2, Vdr, Pdx1, Fkbp1b and Abcc8, suggesting global β-cell defects in STZ-treated islets. |
| 737 | 23828045 | When a pancreas-targeted adeno-associated virus (AAV) vector was employed for long-term Glp-1 gene delivery, pancreatic GLP-1 expression protected mice from STZ-induced diabetes through preservation of the β-cell mass. |
| 738 | 23828045 | Upon pancreatic GLP-1 expression, upregulation of Cxcl13 and Nptx2 was observed in STZ-damaged islets, but not in untreated normal islets. |
| 739 | 23828045 | Given the pro-β-cell-survival effects of Cxcl12 (Sdf-1) in inducing GLP-1 production in α-cells, pancreatic GLP-1-mediated Cxcl13 induction might also play a crucial role in maintaining the integrity of β-cells in damaged islets. |
| 740 | 23838847 | The mRNA expression of lipid and glucose metabolism genes was changed upon the treatment of human primary adipocytes with SPIONs. mRNA of GULP1, SLC30A8, NEGR1, SEC16B, MTCH2, MAF, MC4R, and TMEM195 were severely induced, whereas INSIG2, NAMPT, MTMR9, PFKP, KCTD15, LPL and GNPDA2 were down-regulated upon SPIONs stimulation. |
| 741 | 23900975 | Currently, four major molecular targets ([pro]insulin, GAD65, IA-2, and ZnT8) have been confirmed, with approximately 94% of all subjects with a clinical diagnosis of type 1 diabetes expressing autoantibodies to at least one of these molecules at clinical onset. |
| 742 | 23974918 | The assay was validated with serum samples from 227 newly diagnosed diabetic children; 68 prediabetic children who were prospectively followed to T1D; 130 nondiabetic children with confirmed islet autoantibodies to insulin, GAD65, IA-2, and/or ZnT8 longitudinally followed for 12 ± 3.7 years; and 181 age-matched, healthy, antibody-negative children. |